
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Cadila Healthcare

10 August 2004 | News



Rank 15.....Cadila Healthcare

Revenue: 55 crore

Successful Formulations



CEO: Pankaj R Patel

Revenue: 55 crore

Start-up year: 1995

Business: Production and marketing of vaccines, diagnostics and biologicals

Address: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380 015, Tel: 91-79-26868100, Fax: 91-79-26862366

Website: www.zyduscadila.com

Vital stats

Patents	Number
Indian	41
International	42

Indian Immunologicals Limited (IIL), a wholly owned subsidiary of National Dairy Development Board, was set up in 1983, under the " Operation Flood " program, to meet the growing demand for Foot and Mouth Disease (FMD) vaccine in India. IIL is probably the first and only veterinary biological unit in India to obtain both ISO 9002 and Good Manufacturing Practices (GMP) Certification as per World Health Organization (WHO) GMP guidelines. It has a set up modern plant at Hyderabad with technology from Wellcome Foundation, UK. This plant has an installed production capacity of 25 million quadrivalent doses of FMD vaccine that makes it the second largest plant in the world.

Indian Immunologicals, one of the top 10 animal health companies in India and a market leader in veterinary biologicals, manufactures a wide range of veterinary biologicals, animal health products and feed additives required by the veterinary profession. Apart from domestic sales, the company also exports its products, especially vaccines, to several countries in Asia, Middle East and Africa.

Indian Immunologicals has divided its domestic operations into three strategic business units: Institution (government, co-operatives/milk-unions), Livestock and Petlife. The last two business units focus on prescription and retail markets while the former caters to institutional business. Its products are marketed by 500 distributors and more than 5000 retailers across the country.

Research applied to preventive veterinary medicine has led to various developments at its R&D center. With a dedicated team of scientists and professionally trained staff, it has developed many biologicals and animal health products and introduced theileriosis vaccine, rabies tissue culture vaccine, oil adjuvant FMD vaccine and combined canine vaccines.

Besides a range of veterinary vaccines it offers diagnostic, dewormers and general formulations. IIL products are being exported to countries like Malaysia, Iraq, Turkey, Syria, Jordan, Sri Lanka, Bangladesh, Nepal, UAE, Oman, Bahrain, Yemen, Qatar, Turkey and Taiwan apart from a number of countries in Africa and Latin America. Recognizing the volume of exports to a large number of countries, it bagged the second best exporter award in the commodity group Drugs Pharmaceuticals and Chemicals for the year 1999-2000. IIL is working on recombinant vaccines for animal and human diseases, DNA vaccines and monoclonal antibodies. IIL has entered the human biological market with "Abhayrab", India's first purified vero cell tissue culture rabies vaccine.

The investments during the year stood at Rs 33 crore of which Rs 8 crore was invested on R&D and remaining on infrastructure development. The scientific team at IIL has increased to 20 during 2003-04 from 12 in the last year. Its total work force has increased from 442 in 2002-03 to 514 in 2003-04. So far it has filed 7 international patents on noval combination DNA rabies vaccine. And one patent has already been granted.

The IIL has been doing well as its sales have been growing year-on year. The total sales turnover for 2003-04 stood at Rs 65.76 (including Rs 56.7 crore from biotech products).